Features

FimmCyte, a pioneering women's health biotech, announces an investment of 1 million CHF as a convertible loan from the UZH Life Sciences Fund (LSF). FimmCyte’s…

BASEL, Switzerland, 18 January 2024 - Synendos Therapeutics AG, a world leader in innovative Endocannabinoid System (ECS) treatments, today announces that it has received approval…

Basel, Switzerland – Alentis Therapeutics , a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that Dr. William…

Novo Nordisk has become the latest partner to join BaseLaunch. Novo Nordisk joins other world-class pharma, venture fund and biotechnology partners - Roche, Johnson &…

Basel, Switzerland, 13 December, 2023 – Engimmune Therapeutics AG (“Engimmune”), a world-class developer of soluble T-cell receptor drugs (‘TCRs’) to treat solid tumours, is pleased…

Ferring Pharmaceuticals and PharmaBiome announced a research & development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. The deal provides Ferring…

TOLREMO today announced that the first patient has been dosed in its first-in-human clinical trial evaluating the safety and tolerability, pharmacokinetics, and pharmacodynamics of its…

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma.  Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharma…

Versameb AG, a leading pre-clinical stage biotechnology company, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND)…

This first-in-human study evaluates the safety, tolerability and efficacy of ALE.C04 as a monotherapy and in combination.Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company within our portfolio…